Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
Study Overview
This phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with or without nivolumab in treating patients with kidney cancer that is limited to a certain part of the body (localized). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab before nephrectomy may make the tumor smaller and reduce the amount of normal tissue that needs to be removed, and after nephrectomy to increase survival. It is not yet known whether nivolumab and nephrectomy is more effective than nephrectomy alone in treating patients with kidney cancer.
Study Description
A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
- ClinicalTrials.gov Identifier: NCT03055013
- Protocol Number: 17-704
- Principal Investigator: David McDermott
Recruitment Status
OpenContact the research team to learn more about this study.
Fields marked with asterisk (*) are required